Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 11/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 6/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19986380 | 0.94 | HTR2C (0.38) | FEN1ALOX5APPTGDR2PTGDRHTR2C | |
| SCHEMBL8961823 | 0.93 | HTR2C (0.34) | FEN1ALOX5APPTGDR2PTGDRHTR2C | |
| SCHEMBL20052525 | 0.91 | HTR2C (0.41) | PTGDR2PTGDRHTR2CHTR2BHTR2A | |
| SCHEMBL8934201 | 0.90 | PTGDR2 (0.41) | FEN1ALOX5APPTGDR2PTGDRHTR2C | |
| SCHEMBL19986350 | 0.89 | CYP3A4 (0.37) | PTGDR2PTGDRHTR2CHTR2BHTR2A | |
| SCHEMBL8934980 | 0.88 | HTR2C (0.37) | FEN1ALOX5APHTR2CHTR2BHTR2A | |
| SCHEMBL12733895 | 0.88 | HTR2C (0.37) | FEN1ALOX5APHTR2CHTR2BHTR2A | |
| SCHEMBL14765807 | 0.86 | HTR2C (0.36) | FEN1ALOX5APHTR2CHTR2BHTR2A | |
| SCHEMBL8935065 | 0.86 | HTR2C (0.37) | FEN1ALOX5APHTR2CHTR2BHTR2A | |
| SCHEMBL8962031 | 0.85 | HTR2C (0.35) | FEN1ALOX5APHTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2206695-A1 | TETRA- OR PENTA-CYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, HCN3, FZD7 | FEN1 4226/4885ALOX5AP 1414/4885PTGDR2 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.